A Phase 1 interventional study of Tirzepatide and Placebo in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 2 sites in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-23.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 1, and was the 4th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 180th largest by enrollment of the 232 interventional ones that give a count, is one of 12 that started in 2017, is one of 76 in phase 1, and was the 134th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to determine:
This study includes eight weekly doses of tirzepatide or placebo given as subcutaneous (SC) injections just under the skin. The study will last about 16 weeks (total), including screening and follow-up. This study is for research purposes only and is not intended to treat any medical conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received escalating doses of 2.5 milligrams (mg), 5 mg, 10 mg and 15 mg of tirzepatide administered into the subcutaneous (SC) tissue of the abdominal wall.
Drug: Tirzepatide
Participants received placebo administered into the SC tissue of the abdominal wall.
Drug: Placebo
Administered SC.
Also known as: LY3298176
Administered SC.
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Safety was assessed from time of consent through end of study (up to 85 days). Data presented are the number of participants who experienced 1 or more SAEs considered by the investigator to be related to study drug. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.
Time frame: Baseline through Day 85
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Tirzepatide
Pharmacokinetics (PK): Maximum observed drug concentration (Cmax) of Tirzepatide in plasma.
Time frame: Predose, 8, 24, 48, 72 and 168 hours post dose for Day 1 administration, and Predose, 8, 24, 48, and 168 hours post dose for Day 50 administration
PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide
Area under the concentration versus time curve from time zero to tau (τ) of Tirzepatide (AUC\[0- τ\]), where tau is dosing interval of (0-168 hours).
Time frame: Predose, 8, 24, 48, 72 and 168 hours post dose for Day 1 administration, and Predose, 8, 24, 48, and 168 hours post dose for Day 50 administration
Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose
Change from baseline to 8 weeks in Fasting Plasma Glucose was measured to investigate the PD effect of Tirzepatide after multiple SC doses administered to Japanese patients with T2DM
Time frame: Baseline, Week 8
| Milestone | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) |
|---|---|---|---|---|
| Started | 9 | 12 | 16 | 11 |
| Received at least 1 dose of study drug | 9 | 12 | 16 | 11 |
| Completed | 9 | 11 | 15 | 11 |
| Not completed | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
Safety was assessed from time of consent through end of study (up to 85 days). Data presented are the number of participants who experienced 1 or more SAEs considered by the investigator to be related to study drug. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.
| Participants | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) |
|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 0 | 0 | 0 | 0 |
Pharmacokinetics (PK): Maximum observed drug concentration (Cmax) of Tirzepatide in plasma.
| nanograms per milliliter (ng/mL) | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) |
|---|---|---|---|
| Day 1 | 215 ± 18 | 442 ± 23 | 364 ± 20 |
| Day 50 | 1520 ± 15 | 2270 ± 17 | 838 ± 22 |
Area under the concentration versus time curve from time zero to tau (τ) of Tirzepatide (AUC\[0- τ\]), where tau is dosing interval of (0-168 hours).
| nanograms * hours per mL (ng*hr/mL) | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) |
|---|---|---|---|
| Day 1 | 26100 ± 27 | 54400 ± 16 | 48800 ± 16 |
| Day 50 | 192000 ± 16 | 285000 ± 15 | 104000 ± 19 |
Change from baseline to 8 weeks in Fasting Plasma Glucose was measured to investigate the PD effect of Tirzepatide after multiple SC doses administered to Japanese patients with T2DM
| milligram per deciliter (mg/dL) | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) |
|---|---|---|---|---|
| Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose | -4.0 ± 23.7 | -77.5 ± 24.2 | -72.6 ± 30.9 | -51.7 ± 28.9 |
Collected over Up To 85 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 0/16 (0%) | 0/16 (0%) | 15/16 (93.8%) |
| 5 mg Tirzepatide (Cohort 3) | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| Event | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/9 | 8/12 | 8/16 | 0/11 |
| Decreased appetiteMetabolism and nutrition disorders | 0/9 | 6/12 | 10/16 | 5/11 |
| DiarrhoeaGastrointestinal disorders | 0/9 | 3/12 | 5/16 | 0/11 |
| Abdominal distensionGastrointestinal disorders | 1/9 | 1/12 | 0/16 | 3/11 |
| Abdominal discomfortGastrointestinal disorders | 0/9 | 2/12 | 4/16 | 0/11 |
| DyspepsiaGastrointestinal disorders | 0/9 | 3/12 | 0/16 | 0/11 |
| HeadacheNervous system disorders | 0/9 | 3/12 | 1/16 | 0/11 |
| Blood triglycerides increasedInvestigations | 2/9 | 0/12 | 1/16 | 0/11 |
| NauseaGastrointestinal disorders | 0/9 | 0/12 | 2/16 | 1/11 |
| VomitingGastrointestinal disorders | 0/9 | 1/12 | 2/16 | 1/11 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(Years) | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) | Total |
|---|---|---|---|---|---|
| Mean | 57.4 ± 11.6 | 56.9 ± 9.5 | 57.7 ± 8.0 | 57.5 ± 7.9 | 57.4 ± 8.8 |
| Sex: Female, Male(Participants) | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 0 | 1 |
| Male | 9 | 12 | 15 | 11 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 12 | 16 | 11 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 9 | 12 | 16 | 11 | 48 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) | Total |
|---|---|---|---|---|---|
| Japan | 9 | 12 | 16 | 11 | 48 |
| Body Mass Index (BMI)(kg/m²) | Placebo | 2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1) | 5 mg/10 mg/15 mg Tirzepatide (Cohort 2) | 5 mg Tirzepatide (Cohort 3) | Total |
|---|---|---|---|---|---|
| Mean | 22.58 ± 2.09 | 25.49 ± 2.75 | 26.10 ± 3.11 | 26.68 ± 3.29 | 25.42 ± 3.16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in May 2018, 6 months.
Results were first posted in Mar 2023, 4 years 9 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 6 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide